Rizvi et al. reported that 62 patients with NSCLC, who received an ICI and acquired a PFS of ≥18 mo, presented significantly better outcomes on the basis of both PD-L1 and TMB in comparison with untreated patients (rate of PD-L1 TPS ≥ 50%: 43% vs. 23% TMB: 12.24 vs. 6.34 Mut/Mb) [51]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.